Author + information
- Qi Jianyong and
- Minzhou Zhang
Myocardial ischemia-reperfusion (MI/R) can induce myocardial infarction and lethal ventricular arrhythmia. Tirofiban, a specific GP IIb/IIIa inhibitor, is one of the most frequently used agent in treating myocardial infarction after percutaneous coronary intervention. However, there is still no any published papers in vivo studying the direct effect of tirofiban on MI/R injury in mice up to now.The present study is aimed to assess the direct effect of tirofiban therapy for cardiac protection in a murine model of MI/R injury in vivo.
Tirofiban effects were evaluated in mouse heart preparation using 30-min coronary occlusion followed by 24-h reperfusion and compared among SHAM group (negative model control, n=7), I/R group (positive model control, n=8), VER (I/R with verapamil 20mg/kg pretreatment, positive drug control, n=6), and TIR (I/R with tirofiban 5mg/kg pretreatment, the aim group,n=8). The effects of DLT were characterized in infarction size (IS) compared with risk region (RR) and left ventricle using the Evans blue/triphenyltetrazolium chloride double dye staining method in vivo.
There were no significantly differences in body weight among the four groups(SHAM: 25.6 ± 0.8g, I/R: 26.5 ± 0.7g, VER: 26.2 ± 0.8g, TIR: 28.1 ± 0.9g, P>0.05),respectively. The ratio of IS to RR was significantly smaller in the TIR and VER groups than the I/R group (I/R: 40.6±4.3%, VER: 15.1±2.6%, TIR:20.6± 3.7, P<0.01), the ratio of IS to left ventricle was also reduced in the TIR and VER groups(I/R: 18.3±2.8%, VER: 6.6±0.8%, TIR:7.0± 1.4, P<0.01), while there were no differences in RR among SHAM, I/R, VER, and TIR four groups (P>0.05). Experiments showed incidence of arrhythmias was reduced in the TIR group (P<0.01).
In conclusion, tirofiban is effective in reducing the infarction size caused by MI/R injury. This is the first study directly studying the in-vivo effect of tirofiban on MI/R injury in mice, which results provided an experimental basis for clinical application of tirofiban in reducing I/R injury.